Search academic texts

Information × Registration Number 0200U001156, 0197U001111 , R & D reports Title Development and preclinic investigations of low-molecular nonprotein immunotrophic factor "splenoside" popup.stage_title Head Tron'ko M.D.,Olijnyk B.V., Registration Date 21-01-2000 Organization V.P.Komisarenko Institute of Endoсrinology and Metabolism popup.description2 Analogous processes are developing in the thymus a week later. T-cell activation is accompanied with an increase in thiol groups and inhibition of Ca2+ATPase activity. Mitogenic effeсt of Splenoside is realized by hypoxantin accumulating in the cell suspension during stimulation process with catabolism factor of adenylic asid. The combined usage of both hypoxantin and Splenoside increases the proliferative process. This factor accelerates the reduction of the liver functional state in hepatosohepatitis and blood morfological contents in cyclophosphane lymphocytopenia, it has cardiotropic, actoprotective and adaptogeneic properties. Splenoside inhibits immunologic reactivity in animals sensibilized, decreases the activity of guinea pig blood complement, ingibits hypersensitive reaction of delayed type, and increases the intensity of reaction "transplantant against host". Splenoside harmless for the organism was estimated in the experiments of its acute and chronic toxicity and also according to the abse nse of morphofunctional changes in the gastric mucosa, cardiovascular system, blood and hemopoetic system, kidney and liver after a prolonged administration of this preparation. Product Description popup.authors popup.nrat_date 2020-04-03 Close